The role of autologous micrografts injection from the scalp tissue in the treatment of COVID-19 associated telogen effluvium: Clinical and trichoscopic evaluation.

Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-8019 (Electronic) Linking ISSN: 13960296 NLM ISO Abbreviation: Dermatol Ther Subsets: MEDLINE

Publication: July/Aug. 2008- : Hoboken, NJ : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard, c1996-

Alopecia Areata*/etiology ; Alopecia Areata*/surgery ; Alopecia Areata*/virology ; Autografts* ; COVID-19*/complications ; COVID-19*/virology ; Hair Follicle*/transplantation ; Microsurgery* ; Scalp*/transplantation; Adult ; Follow-Up Studies ; Humans ; SARS-CoV-2 ; Stem Cell Transplantation ; Time Factors

The clinical presentation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 COVID-19) varies from asymptomatic infection to a life-threatening, multiorgan disease. One of these manifestations is telogen effluvium (TE) which is characterized by diffuse hair loss occurring in patients previously infected with SARS-CoV-2 and lasts ~3 months, after which excessive hair loss follows. Hair follicles are known to contain a well-characterized niche for adult stem cells which is the bulge containing epithelial and melanocytic stem cells. Stem cells in the hair bulge, a demarcated structure within the lower permanent portion of hair follicles, can generate the interfollicular epidermis, hair follicle structures, and sebaceous glands. This study aims to evaluate autologous micrografts from scalp tissues as a therapeutic modality in the management of TE caused by COVID-19. Twenty patients of previous COVID-19 infection suffered from TE were included in this study for human follicle stem cells micrograft scalp treatment and they were evaluated after 3 months of treatment and after 6 months. There was significant improvement of the hair thickness and density compared with the start of the treatment and 6 months of follow-up. Autologous micrograft of the scalp showed marked improvement in the treatment of COVID-19 TE.
(© 2022 Wiley Periodicals LLC.)

Am J Pathol. 2006 Jun;168(6):1879-88. (PMID: 16723703)
Int J Dermatol. 2021 Jan;60(1):122-124. (PMID: 33226117)
Dermatol Ther. 2022 Jul;35(7):e15545. (PMID: 35486375)
Cells. 2019 May 16;8(5):. (PMID: 31100937)
Stem Cells Int. 2018 Aug 5;2018:1049641. (PMID: 30154860)
Clin Cosmet Investig Dermatol. 2021 Nov 19;14:1725-1736. (PMID: 34824538)
Dermatol Ther. 2020 Jul;33(4):e13648. (PMID: 32445237)
Stem Cell Investig. 2017 Jun 27;4:58. (PMID: 28725654)
Am J Cardiovasc Drugs. 2020 Aug;20(4):311-324. (PMID: 32578167)
Biomed Res Int. 2020 Jan 27;2020:7397162. (PMID: 32071919)
Cureus. 2020 May 27;12(5):e8320. (PMID: 32607303)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Biomedicines. 2019 Apr 08;7(2):. (PMID: 30965624)
Dermatol Ther. 2021 Mar;34(2):e14761. (PMID: 33405302)
Dermatol Res Pract. 2020 Aug 11;2020:9360476. (PMID: 32849867)

Keywords: COVID-19; autologous micrografts; telogen effluvium

Diffuse alopecia

Date Created: 20220429 Date Completed: 20220714 Latest Revision: 20221205

20240829

PMC9111843

10.1111/dth.15545

35486375